Skip to main content
. Author manuscript; available in PMC: 2020 Jul 15.
Published in final edited form as: Cancer. 2019 Apr 5;125(14):2400–2408. doi: 10.1002/cncr.32061

Figure 2: Overall progression-free survival.

Figure 2:

Data are from the all-treated cohort (all randomized patients who received study drug). Kaplan Meier curves depicting progression-free survival for patients treated with axitinib + dalantercept (blue line) vs. axitinib + placebo (red line). CI=confidence interval. HR=hazard ratio. PFS=progression-free survival.